Loading clinical trials...

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women

NCT00205777•Pfizer

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether bazedoxifene acetate is safe and effective in the treatment of osteoporosis in postmenopausal women.

Eligibility

Age

55 - 80 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Must be at least 2 years postmenopausal
•Osteoporotic subjects without vertebral fracture who meet BMD criteria, or Osteoporotic subjects with vertebral fracture

Exclusion Criteria

•Diseases that may affect bone metabolism
•Vasomotor symptoms requiring treatment
•Known history or suspected cancer of the breast
•Active or past history of venous thromboembolic events

Locations (375)

Pfizer Investigational Site

Birmingham, Alabama, United States

Pfizer Investigational Site

Birmingham, Alabama, United States

Pfizer Investigational Site

Birmingham, Alabama, United States

Pfizer Investigational Site

Huntsville, Alabama, United States

Pfizer Investigational Site

Mobile, Alabama, United States

Pfizer Investigational Site

Glendale, Arizona, United States

Pfizer Investigational Site

Phoenix, Arizona, United States

Pfizer Investigational Site

Phoenix, Arizona, United States

Pfizer Investigational Site

Phoenix, Arizona, United States

Pfizer Investigational Site

Phoenix, Arizona, United States

Key Dates

Start Date

December 1, 2001

Primary Completion Date

September 1, 2010

Completion Date

September 1, 2010

Last Updated

April 10, 2013

Enrollment

7,609

ACTUAL participants

Conditions

Osteoporosis

Interventions

Bazedoxifene Acetate

DRUG

Placebo

OTHER

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

NCT06731608

OsteoporosisLower Limb Fracture

View study

RECRUITING

Smart Wearable Device (gaitQ): Walk Better Project

NCT05913219

Parkinson DiseaseStroke+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 10, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

Inclusion Criteria

Exclusion Criteria

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

Smart Wearable Device (gaitQ): Walk Better Project

Step-down Therapy After Long-term Osteoporosis Treatment

Automated Bone Age Estimation From Noncontrast Abdominal CT Using Deep Learning

Effect of Mechanical Loading and Bone Loss on Motor Neuron Activity-H-Reflex Relationship

Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound Device